Pluristem Advances Second Cell Therapy

Pluristem Therapeutics, Inc. has completed development of its second major cell product line and can now begin large-scale manufacturing for anticipated studies in a range of hematologic conditions. The cell product candidate, PLX-RAD, was created using Pluristem’s three dimensional cell expansion technology platform. The company’s first product, PLX-PAD, is currently in clinical trials for the treatment of peripheral artery disease, muscle injury and pulmonary arterial hypertension.
 
“We’ve just completed a two-year development cycle for our PLX-RAD cells, and have also developed new manufacturing equipment, methods and know-how. We believe that our state-of-the-art technology platform can be used to create additional cell products from the placenta, tailored to potentially deliver targeted treatments for a variety of new indications,” stated Zami Aberman, chairman and chief executive officer of Pluristem.  
 
“Our technology platform, robust manufacturing capabilities and broad IP portfolio open the door for potential institutional and commercial partners, and we’re pleased with the level of interest we have received in our technology platform. Pluristem is in a unique position to be a leader in the cell therapy industry,” Mr. Aberman concluded.